Regeneron Slowly Climbs Towards $1000 With Undervalued Market Cap

Regeneron (NASDAQ: REGN) is one of the long term bullish stocks and has an undervalued market cap while its 12 months EPS nearly reaches $20. Other biotech stocks are extremely volatile due to speculations linked to press releases or news for investors. However, dividend-paying REGN moves slowly with little volatility that causes changes in cents.

On over one million shares REGN could rise from $273.46 to $637.07 in the period between 2019 and 2020. Additionally, it has been paying dividends to common stockholders.

Until the winter of 2020 REGN could reach $800 line as it rose almost $200 from May to July. Only long term traders may buy its shares with future expectations to see it at $1000 next year.